Last reviewed 2026-04-23 · How we verify

INEGY

Selective estrogen receptor modulator

Selective estrogen receptor modulator Used for Hormone replacement therapy.

At a glance

Mechanism of action

INGEY is a combination of norethindrone acetate and ethinyl estradiol, which acts as a selective estrogen receptor modulator.

Approved indications

• Hormone replacement therapy

Common side effects

• Vaginal bleeding
• Headache
• Nausea

Key clinical trials

• A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)
• EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089) (PHASE4)
• IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103) (PHASE3)
• Retrospective Evaluation of the Percentage of Subjects Who Have Reached Their LDL-C Objectives After Treatment With INEGY (Study P05103)(COMPLETED)
• Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (PHASE3)
• Effect of Ezetimibe or Simvastatin or Both on Low Densitiy Lipoprotein -Subfractions in Patients With Type 2 Diabetes (PHASE4)
• Effects on NF-κB Activity: High Dose Simvastatin Versus Combination Therapy With Ezetimibe (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• INEGY CI brief — competitive landscape report
• INEGY updates RSS · CI watch RSS
• Organon and Co portfolio CI